JP Morgan maintains Clorox at Underweight, raises price target to $86 from $83

JP Morgan kept its Underweight rating on Clorox but raised its price target to $86 from $83, suggesting a 4.3% downside from the Nov 2 close of $89.90. Recent analyst price targets for Clorox range from $80 to $99.

Original reporting
Published Nov 3, 2026, 5:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 5:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Clorox at Underweight, raises price target to $86 from $83 — source image
Decision brief

The 30-second read

$CLXBearishLow
01

Why it matters

This is a sentiment update rather than a new fundamental disclosure, with the key takeaway being unchanged Underweight positioning alongside a slightly higher target.

02

Market read

Traders may adjust short-term expectations for CLX based on the PT change, but the maintained Underweight rating limits upside conviction.

03

What to watch

The article does not state the thesis behind the target change, so traders may discount it relative to any underlying earnings or margin drivers.

Relevance 4/10Novelty 4/10Timing: today’s analyst-note update, no new company fundamentals disclosed

Background

The piece summarizes JPMorgan’s latest rating and price-target adjustment for Clorox and notes the recent range of other analysts’ targets.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

JPMorgan maintained Clorox at Underweight and raised its price target to $86 from $83, implying modest downside versus the Nov 2 close.

Expected impact

Likely mild pressure or limited upside, as the rating stays Underweight even though the price target is raised.

Evidence & confidence

The article provides a PT change and an unchanged rating, which typically leads to small, sentiment-driven repricing rather than a fundamental re-rate.

Market effects

Minimal spillover to consumer staples, since this is a single-name analyst target change without new sector data.

None indicated.

None indicated.

Counterpoint

The raised price target could attract incremental dip-buying if traders interpret it as improving fundamentals, despite the unchanged Underweight.

Key entities

  • Clorox

    Consumer staples company covered by JPMorgan, rated Underweight with a raised price target.

Related articles

$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

$CLXHighAI 8/10

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

$CLXMed

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.